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ABSTRACT (max 300 words): 299  
Background. High-dose melphalan plus autologous stem-cell transplantation (MEL200-
ASCT) is the standard approach in newly diagnosed, transplant-eligible myeloma patients. 
We compared consolidation with MEL200- ASCT versus cyclophosphamide–lenalidomide-
dexamethasone (CRD), and maintenance with lenalidomide-prednisone versus lenalidomide 
alone. 
Methods. This is an open-label, randomized, phase 3 study. We enrolled newly diagnosed, 
transplant-eligible myeloma patients aged ≤65 years. Using a 2-by-2 partial factorial design, 
we randomized patients to consolidation with 6 cycles of CRD (cyclophosphamide 300  
mg/m2 days 1, 8, 15; dexamethasone 40 mg days 1, 8, 15, 22; lenalidomide 25 mg days 1–
21) or 2 courses of melphalan 200 mg/m2 (MEL200-ASCT); and to maintenance with 
lenalidomide-prednisone (lenalidomide 10 mg days 1–21; prednisone 50 mg every other 
day) or lenalidomide alone. The primary endpoint was progression-free survival (PFS). This 
study is registered at ClinicalTrials.gov, number NCT01091831. 
Findings. 389 patients were enrolled between July 6, 2009 and May 6, 2011, with 256 
randomized to consolidation and 223 randomized to maintenance therapy. Median follow-up 
was 52·0 months.  PFS (median: 28·6 versus 43·3 months; HR 2·51, P<0·001) and overall 
survival (OS; 4-year: 73% versus 86%; HR 2·40, P=0·004) were significantly inferior with 
CRD compared with MEL200-ASCT. Median PFS was 37·5 months with lenalidomide-
prednisone versus 28·5 months with lenalidomide alone (HR 0·84, P=0·336); 3-year OS was 
83% with lenalidomide-prednisone versus 88% with lenalidomide maintenance (HR 1·53, 
P=0·210). Grade 3-4 hematologic toxicities (26%versus 84%, P<0·001), gastrointestinal 
toxicities (5%versus 20%, P<0·001) and infections (6%versus 19%, P=0·002) were lower 
with CRD than with MEL200-ASCT. No significant difference in toxicities between 
lenalidomide-prednisone and lenalidomide was noticed.  
Interpretation.  PFS and OS were significantly inferior with CRD compared with MEL200-
ASCT.  Lenalidomide-prednisone maintenance did not significantly improve PFS and OS 




Text word count (max 3000): 2999 
Introduction 
High-dose therapy with autologous stem-cell transplantation (ASCT) prolongs progression-
free survival (PFS) and overall survival (OS) compared with conventional chemotherapy in  
newly diagnosed multiple myeloma (NDMM) patients and is currently the standard of care for 
fit patients <65 years.1-3 Immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) and 
proteasome inhibitors (PIs; bortezomib) significantly improved survival in transplant-eligible 
and -ineligible patients.4-15  Given the survival rate in transplant-ineligible patients and the 
substantial toxicity of high-dose melphalan (melphalan 200 mg/m2 [MEL200]), the role of 
ASCT has become an area of debate, and the comparison with less toxic, oral novel agents-
based treatments a high research priority. Cyclophosphamide-lenalidomide-dexamethasone 
(CRD) showed a partial response rate of 85% and a good safety profile.16 To date, one study 
compared MEL200-ASCT versus melphalan–prednisone–lenalidomide (MPR), showing an 
improvement in PFS and OS with MEL200-ASCT.17 Two other ongoing trials are comparing 
high-dose chemotherapy plus ASCT with bortezomib-melphalan-prednisone and with 
bortezomib-lenalidomide-dexamethasone (Clinicaltrials.gov NCT01208766, NCT01191060). 
IMiDs and PIs have been used as part of maintenance strategies to extend PFS and OS.18 
In four randomized studies, lenalidomide maintenance significantly reduced the risk of 
progression (hazard ratio [HR] 0·34-0·50) in comparison with no maintenance, but the 
survival advantage was inconsistent.13-15,17 A randomized trial showed a significant PFS 
benefit in patients receiving maintenance with pharmacologic (50 mg every other day) vs 
physiologic doses of prednisone.19 Maintenance with thalidomide-prednisone prolonged 
PFS, with conflicting OS results.20,21  
This study aims to compare the efficacy and safety of consolidation with CRD versus 
MEL200-ASCT, followed by maintenance with lenalidomide-prednisone versus lenalidomide 





Patients aged ≤65 years with symptomatic, measurable, NDMM were eligible for study 
inclusion. Other inclusion criteria were: Karnofsky performance status ≥60%; life expectancy 
>6 months; absolute neutrophil count ≥1,500/ml3; platelet count ≥75,000/ml3; normal 
cardiac/pulmonary function; creatinine clearance ≥20 ml/min. Exclusion criteria included 
other malignancies within the past 3 years, and peripheral neuropathy of grade >2. The 
study was approved by the institutional review boards of each participating center, and was 
conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. All 
patients provided written informed consent. 
Study design, randomization and masking 
This was a 2-by-2 partial factorial, randomized, open-label, phase 3 trial. Patients were 
recruited from July, 2009 to May, 2011 at 59 centers in Australia, Czech Republic and Italy. 
A simple randomization sequence, stratified according to International Staging System (ISS) 
stage22 (I/II versus III) and age (≤60 versus 61–65 years), was generated by a computer 
program and implemented into a web-based procedure. All patients were randomized at 
enrollment into one of the four groups, with a 1:1:1:1 ratio, but the results of the random 
assignment were concealed until patients reached the end of the induction period and 
confirmed their eligibility for consolidation and maintenance. Patients and physicians did not 
know the random assignment until that time, (Supplement). 
Procedures 
 
All patients received induction with four 28-day cycles of lenalidomide (25 mg daily on days 
1–21) plus dexamethasone (40 mg daily on days 1, 8, 15, and 22) (Rd). Cyclophosphamide 
and granulocyte colony-stimulating factor were used to mobilize stem cells. The 
consolidation regimen comprised six 28-day cycles of cyclophosphamide (300 mg/m2 on 
days 1, 8, 15), dexamethasone (40 mg on days 1, 8, 15, 22) and lenalidomide (25 mg on 
8 
days 1–21) or two cycles of MEL200- ASCT. Maintenance started within 3 months following 
completion of consolidation and consisted of lenalidomide (10 mg on days 1–21 of each 28-
day cycle) plus prednisone (50 mg every other day) or lenalidomide alone (10 mg on days 
1–21 of each 28-day cycle) administered until progression or the development of 
unacceptable adverse events (AEs). Dose modification guidelines are provided in the 
Supplement.  
 
Role of the funding source 
Celgene provided an unrestricted grant to conduct the study but had no role in study design, 
data collection, analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all the data and had final responsibility for the decision to submit for 
publication.   
Outcomes 
The primary study endpoint was PFS. Secondary endpoints included OS, overall response 
rate, and safety. PFS was calculated until the date of progression, death from any cause 
during treatment, or data censoring at the last date on which the patient was known to be 
progression-free. OS was calculated until the date of either death from any cause or data 
censoring at the last date at which the patient was known to be alive. Response was 
assessed using the International Uniform Response Criteria for Multiple Myeloma.23 AEs 
were graded according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events (version 3·0).24  
Statistical analysis 
The primary comparison was between  CRD and MEL200-ASCT. A design of non-inferiority 
was chosen. With an alpha error of 0·05 (1-sided), 390 patients (195 per  arm) would need to 
be enrolled to have a statistical power of 80% to detect a HR of 1·43 in favor of CRD versus 
MEL200-ASCT (corresponding to a 2-year PFS of 0·65 in both arms), assuming 3 years of 
9 
accrual, a minimum follow-up of 2 year, and a drop-out rate of 5%; 390 patients were 
expected to yield the necessary number of events (N=195) for the primary analysis, 
calculated with the formula of Schoenfeld.25 The secondary comparison was between 
lenalidomide-prednisone and lenalidomide maintenance. We expected that approximately 
230 patients (115 per arm) would be eligible for maintenance. With an alpha error of 0·05 (2-
sided), this sample size had a statistical power of 80% to detect an improvement from 0·70 
to 0·82 in 2-year PFS in favor of lenalidomide-prednisone (corresponding to a HR of 0·55). 
 
To estimate the effect of the complete treatment strategy (induction, consolidation, 
maintenance), PFS and OS since the date of study enrollment were estimated for the four 
groups on all enrolled patients. All comparative analyses were performed with an intention-
to-treat approach, on the two randomized populations: a) the consolidation-phase 
population, including all patients eligible for CRD or MEL200-ASCT (starting time of 
analyses: date of random disclosure); and b) the maintenance-phase population, including 
all patients eligible for lenalidomide-prednisone or lenalidomide maintenance (starting time of 
analyses: date of clinical evaluation after consolidation), (Supplement). One interim analysis, 
according to the O’Brien and Fleming design, was specified by the protocol for the MEL200-
ASCT versus CRD comparison when 78 progression events (40%) had occurred. 
 
The safety analysis population included all patients who received at least one dose of the 
study drugs. Response and safety data were compared by means of the chi-square or the 
Fisher’s exact test, when required. Time-to-event data were analyzed using the Kaplan–
Meier method; treatment groups were compared with the log-rank test. Cox proportional 
hazards models were used to estimate HRs and 95% confidence intervals (CIs) for the main 
comparisons, and Grambsch and Therneau test for testing the proportional hazard 
assumption.26Cox models, adjusted for age and ISS stage, were used to explore any effect 
modification of consolidation or maintenance between different subgroups (including the 
prespecified subgroups by age and ISS stage), using interaction terms. Since Grambsch and 
Therneau test suggested a violation of proportional hazard assumption about the 
10 
comparison CRD versus MEL200-ASCT, the time-varying effect of treatment was evaluated 
in the Cox model according to two periods of post-randomization follow-up: the first 24 
months after randomization, and from 24 months after randomization to the end of follow-up. 
Between-group differences in patient characteristics were evaluated using the Mann–
Whitney U test and the Chi-squared or Fisher’s exact test, as appropriate, for continuous 
and categorical variables, respectively. Statistical analyses were performed using SAS 




Three hundred and eighty-nine patients were enrolled; 387 entered the 
induction/mobilization phase, and 256 remained eligible for consolidation with  CRD or 
MEL200-ASCT; the main reason for discontinuation during induction/mobilization was 
progression. At the end of consolidation, 223 patients were eligible for  maintenance (Figure 
1). Baseline demographics and disease characteristics were well balanced across treatment 
arms (Table 1). At the data cut-off, 236 (39%) patients had progressed or died, 42 patients 
(36%) were receiving lenalidomide-prednisone, and 36 patients (34%) were on lenalidomide 
alone. The median durations of follow-ups are reported in Table 1.  
In the total enrolled population, the median PFS from enrollment was 24·2 months with 
CRD+lenalidomide-prednisone, 27·6 months with CRD+lenalidomide, 37·6 months with 
MEL200-ASCT+lenalidomide-prednisone, and 31·5 months with MEL200-
ASCT+lenalidomide (Figure 2A). The 4-year OS was 68% with CRD+lenalidomide-
prednisone, 76% with CRD+lenalidomide, 77% with MEL200-ASCT+lenalidomide-
prednisone, and 75% with MEL200-ASCT+lenalidomide (Figure 2B). 
After the induction/mobilization phase, the random assignment to  CRD or MEL200-ASCT 
was disclosed for the 256 patients eligible for consolidation. The median PFS was 
significantly shorter with CRD (28·6 months) than with MEL200-ASCT (43·3 months; HR for 
the first 24 months 2·51, 95% CI 1·60–3·94, P<0·001; Figure 2C). The inferiority of CRD was 
less evident after 24 months. The 4-year OS rate was significantly lower with CRD compared 
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with MEL200-ASCT (73% versus 86%; HR 2·40, 95% CI 1·32–4·38, P=0·004; Figure 2D). 
The 3-year OS from consolidation was 87% with MEL200-ASCT and 84% with CRD. 
Subgroup analysis of PFS confirmed the inferiority of CRD versus MEL200-ASCT in most of 
the subgroups analyzed, including the lenalidomide-prednisone and lenalidomide 
populations (P value for interaction=0.58), (Figure S1). Subgroup analysis of OS confirmed 
the inferiority of CRD compared with MEL200-ASCT in the lenalidomide-prednisone and 
lenalidomide populations (P value for interaction=0.21), (Figure S2). Figure S3 showed PFS 
and OS in CRD and MEL200-ASCT arms according to cytogenetic data. 
In the 223 patients eligible for maintenance, the median PFS was longer with lenalidomide-
prednisone (37·5 months) than with R (28·5 months) but the difference was not statistically 
significant (HR 0·84, 95% CI 0·59–1·20, P=0·336; Figure 2E). No significant difference in the 
3-year OS rate was noticed between lenalidomide-prednisone and lenalidomide (83% versus 
88%; HR 1·53, 95% CI 0·79–2·98, P=0·210; Figure 2F).  
The 4-year PFS2 from diagnosis was 47% with CRD+lenalidomide-prednisone, 51% with 
CRD+lenalidomide, 66% with MEL200-ASCT+lenalidomide-prednisone, and 57% with 
MEL200-ASCT+lenalidomide (Figure S4). Analyses of treatment and outcome after relapse 
is reported in the Supplement. 
Response rate improved during consolidation and maintenance (Table S6). At data cut-off, 
the complete response (CR) rate was 23% with CRD+lenalidomide-prednisone, 27% with 
CRD+lenalidomide, 37% with MEL200-ASCT+lenalidomide-prednisone, and 33% with 
MEL200-ASCT+lenalidomide (Table S7). 
During induction, the most frequent grade ≥3 AEs were neutropenia (10%), anemia (8%), 
infections (8%), systemic toxicities (6%) and thrombotic events (5%). Three toxic deaths 
occurred (septic shock, n=2; cardiac failure, n=1) and 16 patients (4%) discontinued 
treatment for AEs.  
 
During consolidation, hematologic grade 3-4 AEs occurred less frequently with CRD than 
with MEL200-ASCT (26% versus 84%, P<0·001). They were mainly neutropenia (24% 
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versus 80%, P<0·001) and thrombocytopenia (5% versus 82%, P<0·001). Grade 3-4 non-
hematologic AEs were less common with CRD than with MEL200-ASCT (23% vs 39%, 
P=0·01). The most frequent were gastrointestinal events (5% versus 20%, P<0·001) and 
infections (6% versus 19%, P=0·002). Although MEL200-ASCT induced a higher rate of 
grade 3-4 AEs, no increase in serious AEs or toxic deaths was noticed (1 toxic death due to 
septic shock was reported with CRD). Four patients (3%) in the CRD arm and 1 patient (1%) 
in the MEL200-ASCT arm discontinued therapy for toxicity.  
 
The toxicity profile of the lenalidomide-prednisone and lenalidomide maintenance was 
similar. The most frequent grade 3-4 hematologic AEs were neutropenia (8% with 
lenalidomide-prednisone versus 13% with lenalidomide; P=0·193), infections (8% with 
lenalidomide-prednisone versus 5% with lenalidomide; P=0·417), systemic AEs (6% vs 2%; 
P=0·174) and vascular AEs (4% with lenalidomide-prednisone versus 2% with lenalidomide; 
P=0·449) (Table 2). In the lenalidomide-prednisone arm, lenalidomide dose-reduction for 
AEs was required in 11 patients (9%); prednisone dose-reduction was required in 42 
patients (36%) (median time to prednisone dose-reduction: 4 months); 6 patients (5%) 
discontinued treatment for toxicity and 3 patients stopped treatment after developing a 
second primary malignancy (SPM) (melanoma, n=1; gastrointestinal, n=1; bladder, n=1). In 
the lenalidomide arm, lenalidomide dose-reduction was required in 23 patients (22%); 8 
patients (8%) discontinued lenalidomide for toxicity and 2 patients stopped treatment after 
developing a SPM (glioblastoma, n=1; breast cancer, n=1), The median duration of 
maintenance was comparable in the 2 groups (Table 3). Compliance with lenalidomide in the 
2 arms was not affected by previous therapy with CRD or MEL200-ASCT (Supplement).  
 
Eighteen patients (5%) developed SPMs. During the screening, one patient developed renal 
cancer. During the induction/mobilization, one patient developed breast cancer, one 
gastrointestinal cancer and one squamous cell carcinoma. During maintenance, seven 
patients developed squamous cell carcinoma (CRD+lenalidomide-prednisone n=1; MEL200-
ASCT+lenalidomide-prednisone, n=3; MEL200-ASCT+lenalidomide, n=3), one a 
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glioblastoma (CRD+lenalidomide), one a renal cancer (CRD+lenalidomide), one had a 
breast cancer relapse (CRD+lenalidomide), one developed a colorectal cancer 
(CRD+lenalidomide-prednisone), one a melanoma (MEL200-ASCT+lenalidomide-
prednisone), one a prostate cancer (MEL200-ASCT+lenalidomide-prednisone), and one a 




In this randomized study with NDMM patients, CRD significantly increased the risk of 
progression or death (HR 2·51) and shortened OS (HR 2·40) compared with MEL200-ASCT. 
With the present follow-up, maintenance with lenalidomide-prednisone did not significantly 
improve PFS or OS compared with lenalidomide alone. These results confirm a net clinical 
benefit of MEL200-ASCT consolidation in comparison with chemotherapy plus oral alkylating 
agents, as demonstrated in a previous trial.17  
 
The benefit on PFS and OS for MEL200-ASCT was independent of the maintenance 
treatment. An increase in hematologic and non-hematologic AEs was noticed with MEL200-
ASCT, but toxicities were manageable and did not increase the rate of early death or 
treatment discontinuation.  Although stem cells were collected from all patients before 
consolidation, ASCT was performed in only 43% of CRD patients at relapse, predominantly 
due to a worsening of clinical condition; this was true in particular for patients >60 years. 
Thus, delaying ASCT until relapse is not always feasible and this option should be 
considered with caution. Furthermore, CRD was associated with a significantly shorter PFS2 
compared with MEL200-ASCT: salvage therapy did not cancel the advantage of upfront 
ASCT. 
 
Response rate after consolidation was comparable between CRD  and MEL200-ASCT. 
Depth of response improved during maintenance in both groups. Higher rates of CR and 
very good partial responses were noticed during maintenance in patients who previously 
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received MEL200-ASCT. This could be related to a delayed response to MEL200-ASCT, as 
suggested by a study showing that time to best response occurs 9 months post-ASCT.27 
Results about CRD versus MEL200-ASCT were comparable to those of the RV-MM-209 trial 
comparing consolidation with melphalan-prednisone-lenalidomide versus MEL200-ASCT. 
Survival rates in the MEL200-ASCT arms of the two trials, and in the chemotherapy-
lenalidomide arms (MPR/CRD) were similar. Yet, CRD showed a lower rate of neutropenia 
compared with MPR.17  
Despite a trend towards a better median PFS with lenalidomide-prednisone (37·5 vs 28·5 
months) the difference was not significant; furthermore, 3-year OS was 83% with 
lenalidomide-prednisone vs 88% with lenalidomide (P=0·210). In previous reports, 
lenalidomide maintenance increased remission duration in comparison with no maintenance, 
with inconsistent OS advantage.13-15 Nevertheless, these studies were not powered to 
determine an OS benefit. The role of prednisone plus IMiDs (thalidomide) has been 
evaluated in two studies, in comparison with prednisone alone/no maintenance, showing an 
improved PFS but an inconsistent OS advantage.20,21 None of the trials published compared 
prednisone plus IMiD with IMiD alone. The advantage of adding steroids to IMiDs during 
maintenance is unclear. The therapeutic efficacy of IMiDs probably originate at least in part 
from the activation of cytotoxic NK-cells. Steroids synergize with lenalidomide to inhibit tumor 
growth but they also inhibit NK-cell activity, even when administered in combination with 
IMiDs.28 
The toxicities with lenalidomide-prednisone and lenalidomide maintenance were 
comparable. Nine percent of patients required lenalidomide dose-reduction in the 
lenalidomide-prednisone arm versus 22% in the lenalidomide arm (p=0.004).  The increase 
in dose-reduction was related mainly to the occurrence of mild cutaneous toxicity and 
neutropenia, less frequent with prednisone administration; the rate of lenalidomide dose-
reduction in both arms was not affected by previous treatment with CRD or MEL200-ASCT. 
Prednisone dose-reductions were required in 36% of patients and the median time to 
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prednisone dose-reduction was short: this may in part explain the absence of a clear long-
term advantage with lenalidomide-prednisone. 
 
The rate of SPMs was low; no between-group differences were noted, except for an increase 
in non-invasive skin cancers during maintenance in the MEL200-ASCT arm. The rate of non-
invasive skin cancers was comparable to the one reported in the RV-MM-209 study.17 No 
hematologic SPMs were observed, similarly to the RV-MM-209 study17 (only one 
hematologic SPM occurred). This incidence is low if compared with the one in the 
CALGB100104 and the IFM0502 studies.13,14 The use of a specific alkylating-free induction 
in the present and the RV-MM-20917 trials may in part explain this difference. 
A limitation of this study was that randomization was performed at enrolment and both 
random were disclosed before consolidation. Only 65% of the enrolled patients were eligible 
for consolidation; our drop-out rate is similar to the rate reported in the phase 3 US 
Intergroup Trial S9321.29 The main reasons for discontinuation during induction were PD and 
the choice of alternative therapies in patients with a suboptimal response. Outcome of 
patients who discontinued during induction was particularly poor (Figure S5). Of note, rate of 
grade 3-4 AEs and toxic deaths were low during induction, confirming the safety profile of 
Rd, as reported in the ECOG E4A03 trial.30 We investigated only lenalidomide, and did not 
include bortezomib in the induction and consolidation. Building on Rd with the association of 
a PI improved response rates with manageable toxicity; this can get more patients into 
transplant. Bortezomib-based combinations with alkylating agents or IMiDs induce a high-
quality response and improve outcomes in transplant-eligible and transplant-ineligible 
patients.5,9 Results of two ongoing studies will shed further light on this issue. The two trials 
are comparing effective drug combinations that include bortezomib plus lenalidomide or plus 
melphalan versus ASCT (CT.gov NCT01208766; CT.gov NCT01191060; NCT01208662).  
 
In conclusion, our results confirm that consolidation with MEL200-ASCT remains the 
preferred therapeutic option in transplant-eligible patients with NDMM. This regimen 
improves PFS and OS at a cost of increased but manageable toxicity. Long-term steroid 
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therapy is not well tolerated in about one-third of patients and, with the present follow-up, the 
addition of prednisone to lenalidomide maintenance did not significantly affect survival.  
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Research in Context 
Evidence before this study 
When this trial was developed, the survival of MM patients had considerably improved over 
the preceding 10 years thanks to the introduction of novel agents (thalidomide, bortezomib 
and lenalidomide). Before the introduction of new drugs, high-dose therapy with ASCT 
proved to be superior to conventional chemotherapy in terms of both PFS and OS in patients 
with newly diagnosed MM, but at a cost of increased toxicity.  The survival rate achieved in 
transplant-ineligible patients with novel agents-based, well tolerated therapy, questioned the 
role of ASCT in younger patients. In particular, the comparison of high-dose chemotherapy 
and ASCT with less toxic, orally administered novel agents-based treatments has become a 
high research priority. We searched PubMed using the terms “multiple myeloma”, “clinical 
trials”, “transplantation”, “proteasome inhibitors”, and “immunomodulatory drugs” for articles 
published in English up to June 2015. Search results showed that only one trial has so far 
addressed this issue, namely the phase 3 RV-MM-PI-209 trial that compared high-dose 
chemotherapy and ASCT with the triplet oral combination MPR. Results of that trial were not 
available when the present trial (CRD versus MEL200-ASCT) was planned. Data from a 
phase 1-2 trial indicated a high response rate with MPR treatment, but a high-rate of 
haematological toxicity. Cyclophosphamide, another alkylating agent efficacious in MM 
patients was considered a good alternative to oral melphalan in combination with 
lenalidomide, given the better safety-efficacy profile (PR rate was 85% and with manageable 
AEs and a reduction in haematological toxicities in comparison with MPR).  
When our trial was designed, thalidomide alone or in association with prednisone had been 
used in other trials as part of maintenance strategy to extend remission, showing a 
prolonged PFS, but conflicting results in terms of OS. Thalidomide use was limited by a 
significant long-term toxicity (neuropathy). Lenalidomide, a more potent second generation 
IMiD with a different safety profile (with rarely reported neuropathy), was considered an 
optimal drug to be used as continuous treatment to prolong remission duration. Steroids 
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were also evaluated as maintenance therapy: pharmacologic doses (50 mg every other day) 
of prednisone during maintenance significantly improved PFS in comparison with physiologic 
doses. The combination of lenalidomide plus prednisone, given the synergistic antitumor 
activity of steroids, was deemed a valuable alternative option to lenalidomide alone. In 
addition, our PubMed search found that no other trial has so far compared the efficacy and 
toxicity of prednisone plus lenalidomide with lenalidomide alone. 
 
Added value of this study 
This study showed the inferiority of CRD vs MEL200-ASCT. MEL200-ASCT significantly 
improved PFS and OS in NDMM. An increase in AEs was noticed with MEL200-ASCT, but 
toxicities were manageable and did not increase the rate of early death or treatment 
discontinuation. Our results confirmed the role of MEL200-ASCT in the novel agent era, in 
comparison with oral chemotherapy plus lenalidomide, strengthening the results of the 
phase 3 RV-MM-PI-209 trial published in 2014. Furthermore, our results showed that 
transplant at relapse is no more a feasible option in around 50% of the patients. In addition, 
this is the first trial comparing the efficacy and toxicity of prednisone plus lenalidomide with 
lenalidomide alone. The high survival rate achieved with continuous treatment is comparable 
with the results of other trials evaluating lenalidomide maintenance. Despite an early benefit 
with the association of steroids plus lenalidomide, the long-term use of steroids is not well 
tolerated, and does not provide a significant survival advantage in comparison with 
lenalidomide alone. 
Implication of all the available evidence 
Our results suggest that high-dose chemotherapy and transplant should still be considered a 
standard treatment, even in the era of novel agents, if compared with oral chemotherapy 
plus lenalidomide. Around 50% of patients considered eligible for high-dose chemotherapy 
and ASCT at diagnosis may no longer be eligible for ASCT at relapse; clinicians should keep 
22 
into account this possibility, together with the high efficacy of upfront ASCT, when selecting 
the treatment strategy. Maintenance with lenalidomide alone is a well-tolerated treatment, 
and the addition of long-term steroids does not induce any significant advantage. Two 
ongoing trials are comparing combinations that include a proteasome inhibitor plus 
lenalidomide or plus melphalan versus ASCT; those studies aim to evaluate the benefit of 
early versus late transplant, and the effects of different durations of maintenance therapy. 

















  N % N % N % N % N % 
Age-year                   
Median (range) 57 (18-65)  56 (36-65)   57 (32-65)   57(33-64)   56(37-65)   
IQR 53-61  51-61   53-62   53-61   51-61   
Gender                    
Male 196 50 59 46 61 48 58 50 50 47 
ISS Stage                   
I 170 44 58 45 64 50 60 51 51 48 
II 148 38 48 37 45 35 43 37 39 37 
III 71 18 23 18 18 14 14 12 17 16 
Karnofsky PS            
70-100% 334 86 115 89 106 83 105 90 88 83 
60-70% 55 14 14 11 21 17 12 10 18 17 
Creatinine (mg/dL)                   
Median (range) 0·9 (0·38-3·2)  0·9 (0·5-2·2)   0·9(0·48-3·2)   0·9(0·48-1·6)   0·9(0·58-3·2)   
IQR 0·8-1·1  0·8-1·1   0·7-1·1   0·7-1·1   0·7-1·1   
Missing data   21 5 5 4 3 2 8 7 5 5 
LDH (U/L)                   
Median (range) 243 (6-1143)  233 (64-1104)   259 (6-649)   258(61-649)   243(6-1104)   
IQR 170-326  166-322   187-330   17-334   164-322   
Missing data   54 14 20 16 10 8 17 15 17 16 
Hemoglobin g/L                   
Median (range) 11·3 (5·1-17·1)  11·4 (6·3-17·1)   11·6(6·04-17)   11·9(7·8-17)   11·2(6·3-15·1)   
IQR 9·6-12·7  9·7-13·1   9·9-13·0   10·2-13·4   9·6-12·7   
Missing data   18 5 6 5 9 7 2 2 5 5 
Platelet (x10^3/L)                   
Median (range) 232(75-723)  236 (76-679)   247 (94-723)   247(94-679)   241(75-723)   
IQR 188-297  189-297   196-307   199-297   194-316   
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Missing data   0 0 0 0 0 0 0 0 0 0 
Cytogenetic features                   
Deletion 17p 29 8 10 8 6 5 4 3 8 8 
Translocation (4;14) 41 11 17 13 11 9 15 13 5 5 
Translocation (14;16) 19 5 6 5 6 5 5 4 7 7 
High-risk  80 21 30 23 23 18 22 19 19 18 
Missing data 106 27 31 24 30 24 23 20 27 26 
R-ISS Stage 
R-ISS 1 66 17 23 18 30 24 29 25 20 19 
R-ISS 2 193 50 93 72 91 72 59 50 51 48 
R-ISS 3 18 5 6 5 4 3 3 3 3 3 
Not evaluable 110 28 7 5 2 1 26 22 32 30 
Median time from enrollment 
(months) -  6·0  5·9  12·9  13·1  
Median duration of follow-up from 
enrollment (months) 52·0  -  -  -  -  
Median duration of follow-up from 
consolidation (months) -  46·9  47·9  -  -  
Median duration of follow-up from 
maintenance (months) -  -  -  41·0  42·3  
 
IQR, interquartile range; ISS, International Staging System; R-ISS: revised International Staging System; MEL200-ASCT,melphalan 200 mg/m2 
plus autologous stem cell transplantation; CRD, cyclophosphamide-lenalidomide-dexamethasone, PS, Performance Status. Percentages may 
not total 100 because of rounding. 
 
 
Table 2 Most frequent grade ≥3 adverse events according to treatment phase 
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  N % N % N % N % N % 
At least 1 hematologic 
AE   63 
 
16 34 26 107 84 11 9 15 14 
anemia   29 8 3 2 18 14 1 1 0 0 
neutropenia   40 10 31 24 102 80 9 8 14 13 
thrombocytopenia   8 2 6 5 104 82 1 1 0 0 
At least 1 hematologic 
SAE   3 1 2 2 0 0 0 0 0 0 
               
At least 1 non-
hematologic AE   104 27 30 23 49 39 33 28 20 19 
infection   31 8 8 6 24 19 9 8 5 5 
gastrointestinal   17 4 6 5 25 20 4 3 0 0 
cardiac   10 3 2 2 2 2 0 0 2 2 
vascular   19 5 1 1 0 0 5 4 2 2 
systemic   22 6 6 5 6 5 7 6 2 2 
dermatologic   13 3 4 3 0 0 1 1 3 3 
At least 1 non-
hematologic SAE  54 14 13 10 9 7 13 11 10 9 
Discontinuation due to 
AEs  16 4 4 3 1 1 6* 5 8^ 8 
 
AE, adverse event; SAE, serious adverse event; MEL200-ASCT,melphalan 200 mg/m2 plus autologous stem cell transplantation; CRD, 
cyclophosphamide-lenalidomide-dexamethasone. Percentages may not total 100 because of rounding. ^3 patients who previously received 
CRD and 5 patients who previously received MEL200-ASCT; *3 patients who previously received CRD and 3 patients who previously received 
MEL200-ASCT. 
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  N % N % 
Lenalidomide dose         
Full dose 10 mg 106 91 83 78 
Reduced dose 11* 9 23* 22 
7·5 mg 3 3 7 7 
5 mg 8 7 16 15 
Median duration of treatment (months) 28·9   25·3   
Reasons for dose reduction         
Hematological AEs 1 1 8 8 
Dermatologic AEs 1 1 5 5 
Infections 0 0 4 4 
Gastrointestinal AEs 5 4 3 3 
Peripheral neuropathy 2 2 1 1 
Other reasons 2 2 2 2 
     
Prednisone dose      
Full dose 50 mg 75 64     
Reduced dose 42 36     
25 mg 27 23     
12·5 mg 15 13     
Median duration of treatment (months) 26·1       
Reasons for dose reduction         
Psychiatric disorders 10 9     
Endocrinopathy 6 5     
Hyperglycemia 4 3     
Cardiovascular AEs 5 4   
Gastrointestinal AEs 3 3   
Musculoskeletal AEs 2 2   
Weight gain 2 2   
Other reasons  10 9   
 












Figure 1. Consort Diagram: Randomization, Treatment Phases, and Follow-up of 
Patients 
389 patients  enrolled
387 entered  induction/mobilization phase
2 not eligible:
1 withdrew consent 
1 SPM
256 eligible and randomized to consolidation with MEL200-ASCT or CRD




5  lost to follow up
67 disease progression
18  withdrew consent
22 other
127  received MEL200-ASCT 129  received CRD
117 eligible for maintenance with 
lenalidomide-prednisone vs. lenalidomide
23 discontinued during  
consolidation therapy
2 died


































33 discontinued during  
maintenance phase
3 toxic effects
27  disease progression
1 withdrew consent
2 SPM
37 discontinued during  maintenance 
phase








MEL200-ASCT, 2 courses of melphalan 200 mg/m
2
 plus autologous stem cell transplantation; 6 cycles of CRD, 


















Figure 2. Kaplan-Meier Estimates of Progression-Free Survival and Overall Survival 
for the Population Eligible and Randomized to CRD  or MEL200-ASCT, and to 
lenalidomide-prednisone vs lenalidomide maintenance 
Panel A shows progression-free survival from diagnosis with CRD followed by lenalidomide-
prednisone maintenance, CRD followed by lenalidomide maintenance, MEL200-ASCT 
followed by lenalidomide-prednisone maintenance, and MEL200-ASCT followed by 
lenalidomide maintenance. Panel B shows overall survival with CRD followed by 
lenalidomide-prednisone maintenance, CRD followed by lenalidomide maintenance, 
MEL200-ASCT followed by lenalidomide-prednisone maintenance, and MEL200-ASCT 
followed by lenalidomide maintenance. Panel C shows progression-free survival from the 
start of CRD or MEL200-ASCT. Panel D shows overall survival from the start of CRD or 
MEL200-ASCT. Panel E shows progression-free survival from the start of lenalidomide-
prednisone maintenance or lenalidomide maintenance. Panel F shows overall survival from 
the start of lenalidomide-prednisone maintenance or start of lenalidomide maintenance. 
MEL200-ASCT: melphalan 200 mg/m2 plus autologous stem cell transplantation; CRD 
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Study design, randomization and masking 
An informatics system randomly assigned patients to treatment at enrolment, but disclosed 
the treatment allocation only when the patient was eligible for consolidation. Patients were 
eligible for consolidation if they did not experience unacceptable toxicity and did not 
experience progression during the induction/mobilization phase and if they collected an 
adequate amount of stem cells for a double ASCT. Both the patient and the treating 
physician did not know the consolidation and maintenance arm until that time.  
Procedures: dose modification guidelines  
The dose of lenalidomide, cyclophosphamide, prednisone or dexamethasone were reduced 
in case of pre-specified hematological or non-hematological drug related toxicities (mainly 
grade 3-4 toxicities). Steroids related toxicities were managed according to specific 
guidelines (the drug could be reduced for specific grade >2 toxicities). Dose reductions were 
required also for delay between 2 to 4 weeks from planned cycle date. Table 1S, 2S, 3S and 
4S show dose reductions steps of lenalidomide, cyclophosphamide, dexamethasone and 
prendnisone.  
Procedures: treatment after relapse 
Patients experiencing progressive disease (PD) during treatment were treated according to 
local standards and maintained in the trial for later outcome evaluations. Treatment with 
ASCT at relapse was suggested for patients who were randomized to CRD, but not 
mandatory. The decision on second-line therapy was left to the treating physician. Data on 
second-line therapy (type, date of start of second-line therapy, progression after second-line) 
were prospectively collected for all patients enrolled in the trial.  
Statistical Analyses 
The comparative analyses of CRD vs MEL200-ASCT included only patients for whom 
randomization was disclosed and the starting time of analyses was the date of disclosure of 
randomization. The comparative analyses of maintenance with lenalidomide-prednisone vs 
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lenalidomide alone included all patients eligible for lenalidomide-prednisone or lenalidomide 
maintenance. Patients were considered eligible for maintenance if they did not experience 
unacceptable toxicity and did not experience progression during consolidation phase; the 
starting time of analyses was the date of clinical evaluation after the consolidation phase. 
In a post-hoc analysis not prespecified in the protocol, we evaluated progression-free 
survival-2 (PFS2). PFS2 endpoint included all patients randomized in the first line of therapy 
to the 4 treatment arms. It is the time from randomization in the first line of therapy to 
progression/death after second line. Patients who progressed after the first line of therapy 
received a second-line therapy and progressed/died after second-line therapy are 
considered as failures at the date of progression/death after second line, whichever comes 
first. Patients who died after the first line of therapy without progressing or receiving a 
second–line therapy  are considered as failures at the date of death. Patients who 
progressed after the first line of therapy, received a second-line therapy and did not 
progress/die after second line are censored at the date they are known to be in 
remission/alive. Patients in remission after or during the first line of therapy are censored at 
the last date they are known to be in remission.  
In a subsequent post-hoc analysis not prespecified in the protocol, we evaluated OS from 
relapse. OS from relapse was calculated from the date of first relapse until the date of either 




Lenalidomide and prednisone dose-reduction according to previous treatment with 
CRD or MEL200-ASCT 
In the RP arm, 11 patients required lenalidomide dose reductions: 5 patients received 
previous consolidation with CRD and 6 patients received previous consolidation with 
MEL200. In the same arm, 42 patients required prednisone dose-reduction: 16 patients 
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received previous consolidation with CRD and 26 patients received previous consolidation 
with MEL200. 
In the R arm, 23 patients required lenalidomide dose reductions: 10 patients received 
previous consolidation with CRD and 13 patients received previous consolidation with 
MEL200.  
Post-hoc analysis of outcome of patients ineligible at consolidation 
One-hundred and thirty-one patients went off-protocol before consolidation. Of the 67 
patients who progressed before consolidation, 26 (39%) received ASCT, 33 (49%) received 
bortezomib-based regimen, 8 (12%) other therapies. Of the 66 patients who went off- 
protocol before consolidation for reasons other than progression, 19 (29%) received ASCT, 
18 (27%) received bortezomib-based regimen, 8 (12%) other therapies; 21 (32%) patients 
did not received any other therapy (these include patients who went off protocol for 
unacceptable adverse events, consent withdrawal, lost to follow-up, death). 
Outcome of patients who went off protocol before consolidation was particularly poor. 
Figures 5S shows OS in patients eligible for consolidation and in patients who were not (that 
were those patients who went off-protocol before consolidation). The 4-year OS was 82% in 
patients who proceeded with consolidation and 55% in patients who discontinued before 
consolidation (Figure S5).  
Outcome after relapse 
Table S5 shows treatment at relapse in the 4 treatment arms. In the CRD arm, only 43% of 
patients received ASCT at relapse; 60% of them were older than 60 years of age. 
The 3-year OS from relapse in the 4 treatment arms was 44% with CRD+lenalidomide-
prednisone, 67% with CRD+lenalidomide, 50% with MEL200-ASCT+lenalidomide-
prednisone, and 62% with MEL200-ASCT+lenalidomide. No significant differences were 
noticed.  
We analysed OS from relapse in patients who relapsed from CRD according to treatment 
administered at relapse, to see if transplant at relapse, when applicable, could improve 
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outcome. The 3-year OS from relapse in patients who received ASCT at relapse was 60%; 
















Table S1. Lenalidomide dose reduction steps*  
 
Starting dose Lenalidomide  25 mg daily for 21 days every 28 days 
Dose Level-1 Lenalidomide  15 mg daily for 21 days every 28 days 
Dose Level-2 Lenalidomide  10 mg daily for 21 days every 28 days 
Dose Level-3 Lenalidomide  7.5 mg daily for 21 days every 28 days 
Dose Level-4        Lenalidomide  5 mg daily for 21 days every 28 days 
Dose Level-5 Lenalidomide  2.5 mg daily for 21 days every 28 days 
 
*Lenalidomide dose reduction during maintenance follows the steps resumed in the table, considering a starting dose of 10 mg. 
 
Table S2 Cyclophosphamide dose reduction steps  
 
Starting dose Cyclophosphamide  300 mg/m2 days 1,8,15 
Dose Level-1 Cyclophosphamide  200 mg/m2 days 1,8,15 






Table S3 Dexamethasone dose reduction steps 
  
Starting dose Dexamethasone 40 mg daily (d 1,8, 15 and 22) every 28 days 
Dose Level-1 Dexamethasone 30 mg daily (d 1, 8, 15 and 22) every 28 days 
Dose Level-2 Dexamethasone 20 mg daily (d 1, 8, 15 and 22) every 28 days 
 
Table S4 Prednisone dose reduction steps 
 
Starting dose Prednisone 50 mg every other day 
Dose Level-1 Prednisone 25 mg every other day 


























 N % N % N % N % 
ASCT 30 50 23 37 13 24 12 19 
bortezomib based 15 25 15 24 8 15 7 11 
IMiD based 0 0 0 0 0 0 2 3 
Other 15 25 8 13 5 9 3 5 
No ASCT 31 50 40 63 41 76 51 81 
bortezomib based 27 44 31 49 34 63 36 57 
IMiD based 2 3 5 8 3 6 12 19 
Other 2 3 4 6 4 7 3 5 
ASCT, autologous stem cell transplantation; IMiD, immunomodulatory drug; MEL200-ASCT, melphalan 200 mg/m
2
 plus autologous stem cell transplantation; 
































 N % N % N % N % N % 
CR 8 2 15 12 17 13 35 30 32 30 
VGPR 48 12 50 39 52 41 39 33 41 39 
≥VGPR 56 14 65 50 69 54 74 63 73 69 
PR 220 57 50 39 46 36 30 26 24 23 
≥PR 276 71 115 89 115 91 104 89 97 92 
SD 98 25 11 9 7 6 5 4 4 4 
PD 2 1 0 0 0 0 1 1 1 1 
NA 11 3 3 2 5 4 7 6 4 4 
 
CR, complete response; VGPR, very good partial response, PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; Rd, 
lenalidomide-dexamethasone; MEL200-ASCT, melphalan 200 mg/m
2
 plus autologous stem cell transplantation; CRD, cyclophosphamide-lenalidomide-











Table S7 Best Response at data cut-off in the four treatment arms. 













N=57   
 N % N % N % N % 
CR 13 23 13 27 22 37 19 33 
VGPR 14 25 15 31 25 42 26 46 
≥VGPR 27 47 28 57 47 78 45 79 
PR 20 35 15 31 10 17 9 16 
≥PR 47 82 43 88 57 95 54 95 
SD 3 5 4 8 2 3 0 0 
PD 1 2 0 0 0 0 1 2 
NA 6 11 2 4 1 2 2 4 
CR, complete response; VGPR, very good partial response, PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; Rd, 
lenalidomide-dexamethasone; MEL200-ASCT, melphalan 200 mg/m
2
 plus autologous stem cell transplantation; CRD, cyclophosphamide-lenalidomide-










































Subgroup analysis of PFS: CRD vs MEL200-ASCT comparison.  MEL200-ASCT, 
melphalan 200 mg/m
2
 plus autologous stem cell transplantation; CRD, cyclophosphamide-




























































Subgroup analysis of OS: CRD vs MEL200-ASCT comparison. MEL200-ASCT, 
melphalan 200 mg/m2 plus autologous stem cell transplantation; CRD, cyclophosphamide-
















Figure S3 Panel A shows PFS in the CRD arm according to cytogenetic data. Panel B 
shows PFS in the MEL200-ASCT arm according to cytogenetic data. Panel C shows 
OS in the CRD arm according to cytogenetic data. Panel D shows OS in the MEL200-
ASCT arm according to cytogenetic data. MEL200-ASCT, melphalan 200 mg/m2 plus 
autologous stem cell transplantation; CRD, cyclophosphamide-lenalidomide-dexamethasone 
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Figure S4 Kaplan-Meier Estimates of PFS-2 for the Population of in the MEL200-ASCT 
or CRD, and to lenalidomide-prednisone vs lenalidomide maintenance. MEL200-ASCT 
melphalan 200mg/m2 plus autologous stem cell transplantation; CRD cyclophosphamide–
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